Global health agency Unitaid has awarded Medincell a top-up grant of up to $6 million over three years to fund the Phase 1 clinical study of the mdc-STM long-acting injectable treatment. If it proves to be safe, effective and well tolerated, it could have a significant impact on the transmission of malaria in vulnerable populations residing in the most affected areas.
Based on Medincell’s BEPO® technology, mdc-STM is an injectable formulation of ivermectin active for three months aimed at combating the transmission of malaria. A previous grant of $6.4 million was awarded in March 2020 by Unitaid to finance the research, formulation and preclinical studies of the program, carried out by Medincell and the members of the consortium gathered around the project, the IRD , the IRSS and the CIRDES.